
Opinion|Videos|November 25, 2024
Shared Decision-making for Selection of FDA-approved Therapies for NMOSD
Author(s)Michael Levy, MD, PhD
Key Takeaways
- Efficacy, safety, dosing frequency, and patient-specific factors are key in selecting NMOSD therapies.
- Eculizumab and ravulizumab may be preferred for patients with severe relapses or contraindications to B-cell depletion.
A panelist discusses how when treating NMOSD, neurologists should consider the patient's clinical characteristics, safety profiles, administration requirements, and cost-effectiveness when selecting between FDA-approved therapies such as eculizumab, inebilizumab, satralizumab, ravulizumab, and rituximab. Shared decision-making is crucial, involving close collaboration between the healthcare team and the patient to develop a personalized treatment plan that considers the patient's overall well-being.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What factors should be considered when choosing between other available FDA-approved therapies (eculizumab, inebilizumab, satralizumab, and ravulizumab) for patients with NMOSD?
- What clinical characteristics can help guide neurologists in selecting eculizumab or ravulizumab versus rituximab?
- Discuss shared decision-making when managing patients with APQ4+ NMOSD.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis
2
Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis
3
Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers
4
Using Human iPSC Models to Dissect PIRA Mechanisms in Progressive Multiple Sclerosis: Valentina Fossati, PhD
5











